Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT06090903
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Biospecimen Collection — PROCEDURE
    patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
  • Magnetic Resonance Imaging — PROCEDURE
    Undergo MRI scan
  • Medical Chart Review — OTHER
    Review Medical Chart

Study Details

This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.

Key Dates

Start date
Apr 14, 2022
Status verified
Nov 2025
Primary completion
Apr 18, 2027
Completion
Apr 18, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING

Arms

  • Experimental: Screening (MRI)
    Patients undergo one MRI scan over approximately 1 hour prior to surgery.

Primary Outcome Measure

Decorin (DCN) expression [ Time Frame: Up to 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCLA / Jonsson Comprehensive Cancer CenterLos AngelesCalifornia90095
Benjamin M. Ellingson
[email protected]
310-481-7572
Benjamin M. Ellingson (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
UCLA / Jonsson Comprehensive Cancer Center· Los Angeles, CA

Related Studies